The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension
Open accessAbstract
The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes remains unknown. COVID-19 patients with hypertension were enrolled to evaluate the effect of RAS inhibitors. We observed that patients receiving ACEI or ARB therapy had a lower rate of severe diseases and a trend toward a lower level of IL-6 in peripheral blood. In addition, ACEI or ARB therapy increased CD3 and CD8 T cell counts in peripheral blood and decreased the peak viral load compared to other antihypertensive drugs. This evidence supports the benefit of using ACEIs or ARBs to potentially contribute to the improvement of clinical outcomes of COVID-19 patients with hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistent with animal models, it was reported that AngII–AT1R axis inhibitors may be beneficial for COVID-19 patients (360–363) to decrease serum IL-6 levels (360).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [360]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Self-citationWu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445
Self-citationLiu, Y., Yang, Y., Zhang, C., Huang, F., Wang, F., Yuan, J., Wang, Z., Li, J., Li, J., Feng, C., et al. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1643-8 · Cited by 2,056
Self-citationStatus of Hypertension in China: Results From the China Hypertension Survey, 2012–2015
Wang, Z., Chen, Z., Zhang, L., Wang, X., Hao, G., Zhang, Z., Shao, L., Tian, Y., Dong, Y., Zheng, C., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032380 · Cited by 1,698
Self-citationAddendum: A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2951-z · Cited by 715
Self-citationAngiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury
Yang, P., Gu, H., Zhao, Z., Wang, W., Cao, B., Lai, C., Yang, X., Zhang, L., Duan, Y., Zhang, S., et al. (2014) · Scientific Reports · doi:10.1038/srep07027 · Cited by 283
Ye, R., & Liu, Z. (2019) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2019.104350 · Cited by 205
Gage, J. R., Fonarow, G. C., Hamilton, M. A., Widawski, M., Martı́nez-Maza, O., & Vredevoe, D. L. (2004) · NeuroImmunoModulation · doi:10.1159/000076766 · Cited by 81
Recent Update of Renin-angiotensin-aldosterone System in the Pathogenesis of Hypertension
Moon, J.-Y. (2013) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2013.11.2.41 · Cited by 81
Research works printed but not linked: 1
- Moon JY. Recent Update of renin-angiotensin-aldosterone. Sys Pathogenesis Hypertens. 2013;11(2):41–45.
Cited by
Sorted by citations
Items 301–400 of 619
Severity of COVID-19 and Treatment Strategy for Patient With Diabetes
Jin, S., & Hu, W. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.602735 · Cited by 14
Yip, C. W., Leung, K.-H., Wong, D., Cheung, D. T. L., Chu, M.-F., Tang, H. S., & Kam, K. M. (2006) · PubMed · Cited by 13
Drugs acting on renin angiotensin system and use in ill patients with COVID-19
Alexandre, J., Cracowski, J., Richard, V. J., & Bouhanick, B. (2020) · Therapies · doi:10.1016/j.therap.2020.05.009 · Cited by 14
Volpe, M., & Battistoni, A. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.07.041 · Cited by 13
Martynowicz, H., Jodkowska, A., Poręba, R., Mazur, G. J., & Wieckiewicz, M. A. (2021) · Dental and Medical Problems · doi:10.17219/dmp/131795 · Cited by 16
A Dual-Route Perspective of SARS-CoV-2 Infection: Lung- vs. Gut-specific Effects of ACE-2 Deficiency
Sajdel, E. M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.684610 · Cited by 13
O uso de inibidores do sistema renina angiotensina aldosterona em pacientes hipertensos com COVID-19
Vieira, M. S., Vieira, A. L. S., Rezende, A. C. A., Pereira, J. C. R., Costa, M. I. A., Nogueira, A. A. D. A., Santos, G. P., Ribeiro, F. F., & Maia, L. F. (2021) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e8779.2021 · Cited by 13
The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets
Casucci, G., Acanfora, D., & Incalzi, R. A. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00808-4 · Cited by 14
Akın, H., Kurt, R., Tufan, F., Swi, A. I. A., Özaras, R., Tahan, V., & Hammoud, G. M. (2020) · Diseases · doi:10.3390/diseases8040041 · Cited by 13
Cai, L., Xi, G., Cao, Y., Ying, P., Hong, L., Zhang, Y., Yi, G., & Fu, M. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4876 · Cited by 14
Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review
Ferrari, F., Martins, V. M., Fuchs, F. D., & Stein, R. (2021) · Clinics · doi:10.6061/clinics/2021/e2342 · Cited by 15
Recognizing risk factors associated with poor outcomes among patients with COVID-19
Rodriguez‐Miguelez, P., Heefner, A., & Carbone, S. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.01.006 · Cited by 13
Candesartan as a tentative treatment for COVID-19: A prospective non-randomized open-label study
Lukito, A. A., Widysanto, A., Lemuel, T. A. Y., Prasetya, I. B., Massie, B., Yuniarti, M., Lumbuun, N., Pranata, R., Pradhana, C. M. L., Wahjoepramono, E. J., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.05.019 · Cited by 14
Almeida, K., Marcelino, C. H. D. S., da Cruz, L. L., Rocha, L. A. S., Falcão, F. C. D. O. S., Santos, J. C., Lima, S. O., & Cândido, E. A. F. (2020) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e4806.2020 · Cited by 12
Buying time: Drug repurposing to treat the host in COVID‐19H
Martin, J. H., Clark, J., & Head, R. J. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.620 · Cited by 12
Khan, K., Reed-Embleton, H., Lewis, J., Bain, P., & Mahmud, S. (2020) · Scottish Medical Journal · doi:10.1177/0036933020951926 · Cited by 12
Georges, J., Cochet, H., Roger, G., Jemâa, H. B., Soltani, J., Azowa, J.-B., Mamou, R., Gilles, F., Saba, J., Prevot, A., et al. (2020) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2020.09.030 · Cited by 12
Novel coronavirus disease in patients with end‐stage kidney disease
Shimada, N., Shimada, H., Itaya, Y., & Tomino, Y. (2020) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.13599 · Cited by 12
Naveed, H., Elshafeey, A., Al‐Ali, D., Janjua, E., Nauman, A., Kawas, H., Kaul, R., Aldien, A. S., Elshazly, M. B., & Zakaria, D. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1852 · Cited by 12
IHEANACHO, C. O., Odili, V. U., & Eze, U. I. H. (2021) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-021-00224-4 · Cited by 13
Dai, X.-C., An, Z., Wang, Z., Wang, Z., & Wang, Y.-R. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.609857 · Cited by 12
Self-citationKaur, U., Chakrabarti, S. S., & Patel, T. K. (2021) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986211011345 · Cited by 15
Wang, H., Peng, S., Ye, Z., Li, P., Li, Q., Shi, X., Zeng, R., Yao, Y., He, F., Li, J., et al. (2021) · Frontiers of Medicine · doi:10.1007/s11684-021-0850-9 · Cited by 12
Self-citationRole of rehabilitation amidst the COVID-19 pandemic: a review
Yu, C., & Helwig, E. J. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03048-1 · Cited by 12
Xie, Q., Tang, S., & Li, Y. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-972 · Cited by 12
A Peek into Pandora’s Box: COVID-19 and Neurodegeneration
Chandra, A., & Johri, A. (2022) · Brain Sciences · doi:10.3390/brainsci12020190 · Cited by 14
The pandemic COVID-19: a tale of viremia, cellular oxidation and immune dysfunction
Rowaiye, A. B., Onuh, O. A., Oli, A. N., Okpalefe, O. A., Oni, S. O., & Nwonu, E. J. (2020) · Pan African Medical Journal · doi:10.11604/pamj.2020.36.188.23476 · Cited by 12
ACE2 enhance viral infection or viral infection aggravate the underlying diseases
Teng, S., & Tang, Q. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.08.002 · Cited by 13
Hoevenaar, M., Goossens, D., & Roorda, J. (2020) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320320979097 · Cited by 12
Wang, T., Tang, R., Ruan, H., Chen, R., Zhang, Z., Sang, L., Su, X., Yi, S., Ni, Z., Hu, Y., et al. (2021) · The Clinical Respiratory Journal · doi:10.1111/crj.13382 · Cited by 12
Self-citationAdamalysins in COVID-19 – Potential mechanisms behind exacerbating the disease
Dias, I. R. D. S. R., Cao, Z., & Kwok, H. F. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112970 · Cited by 12
Primary hypertension, anti-hypertensive medications and the risk of severe COVID-19 in UK Biobank
Pavey, H., Kulkarni, S., Wood, A., Ben‐Shlomo, Y., Sever, P., McEniery, C. M., & Wilkinson, I. B. (2022) · PLoS ONE · doi:10.1371/journal.pone.0276781 · Cited by 14
Haroon, S. M., Subramanian, A., Cooper, J. M., Anand, A., Gokhale, K. M., Byne, N., Dhalla, S., Acosta, D., Taverner, T., Okoth, K., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-05951-w · Cited by 13
Martin, J. H., & Head, R. J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14551 · Cited by 10
Musavi, H., Abazari, O., Safaee, M. S., Variji, A., Koohshekan, B., Kalaki-Jouybari, F., Barartabar, Z., Hakemi, P., & Mahjoub, S. (2021) · Iranian Journal of Allergy Asthma and Immunology · doi:10.18502/ijaai.v20i1.5409 · Cited by 11
Safety and Efficacy of Renin–Angiotensin–Aldosterone System Inhibitors in COVID-19 Population
Sattar, Y., Mukuntharaj, P., Zghouzi, M., Suleiman, A. M., Attique, H. B., Ullah, W., Sana, M. K., Zaher, N., Mehmood, M., Doshi, R. P., et al. (2021) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00462-w · Cited by 11
Correlation of ACE2 with RAS components after Losartan treatment in light of COVID-19
Zaheer, J., Kim, H., & Kim, J. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-03921-5 · Cited by 11
COVID-19 y el sistema renina, angiotensina, aldosterona. Una relación compleja
Alcocer, L. A., Cossío-Aranda, J. E., Verdejo-París, J., Odin-de-los-Ríos, M., Galván‐Oseguera, H., Álvarez‐López, H., & Alcocer-Gamba, M. A. (2020) · Archivos de cardiología de México · doi:10.24875/acm.m20000063 · Cited by 11
Elrayess, M. A., Zedan, H. T., Alattar, R. A., Abusriwil, H. M., Al-Ruweidi, M. K. A. A., Almuraikhy, S., Parengal, J., Hariri, B. A., Yassine, H. M., Hssain, A. A., et al. (2022) · Blood Pressure · doi:10.1080/08037051.2022.2055530 · Cited by 11
Vásquez, V., Martínez, R., Rodríguez-Núñez, K., & Bernal, C. (2024) · Algal Research · doi:10.1016/j.algal.2024.103575 · Cited by 10
Anzola, G. P., Bartolaminelli, C., Gregorini, G. A., Coazzoli, C., Gatti, F., Mora, A., Charalampakis, D., Palmigiano, A., Simone, M. D., Comini, A., et al. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02500-2 · Cited by 10
Kernéis, M., Ferrante, A., Guedeney, P., Vicaut, É., & Montalescot, G. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.09.002 · Cited by 10
Mirbeyk, M., Saghazadeh, A., & Rezaei, N. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-63761-3_13 · Cited by 10
Biberoğlu, S., İpekci, A., Ikızcelı, İ., Çakmak, F., Akdeniz, Y. S., Kanbakan, A., Konukoğlu, D., Bolayırlı, M., Börekçi, Ş., Ürkmez, S., et al. (2021) · Biomarkers in Medicine · doi:10.2217/bmm-2021-0121 · Cited by 10
Alkhemeiri, A., Zaabi, S. M. A., Jeyaseelan, L., El‐Khatib, Z., & Awofeso, N. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192315967 · Cited by 10
COVID-19 and renin-angiotensin system modulators: what do we know so far?
Cruz, A. D. L., Ashraf, S., Vittorio, T. J., & Bella, J. N. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1814143 · Cited by 10
SARS-CoV-2 cell receptor gene ACE2 -mediated immunomodulation in breast cancer subtypes
Bhari, V. K., Kumar, D., Kumar, S., & Mishra, R. (2020) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2020.100844 · Cited by 10
Grinevich, V. B., Kravchuk, Y. A., Ped, V. I., Sas, E. I., Salikova, S. P., Владимировна, Г. И., Ei, T., Sitkin, S. I., Лазебник, Л. Б., Голованова, Е. В., et al. (2021) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-187-3-5-82 · Cited by 12
Huffman, A., Masci, A. M., Zheng, J., Sanati, N., Brunson, T., Wu, G., & He, Y. O. (2021) · Journal of Biomedical Semantics · doi:10.1186/s13326-021-00250-4 · Cited by 9
Nozari, F., & Hamidizadeh, N. (2022) · International Journal of Hypertension · doi:10.1155/2022/5937802 · Cited by 10
Sharma, R., Kumar, A., Majeed, J., Thakur, A. K., & Aggarwal, G. (2022) · The Egyptian Heart Journal · doi:10.1186/s43044-022-00303-8 · Cited by 10
Antagonizing the renin–angiotensin–aldosterone system in the era of COVID-19
Sarzani, R., Giulietti, F., Pentima, C. D., Filipponi, A., & Spannella, F. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02365-5 · Cited by 10
Renin-Angiotensin System Blockade in COVID-19
Bloch, M. J. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.06.003 · Cited by 10
Metabolic Syndrome “Interacts” With COVID-19
Guo, Z., Jiang, S., Li, Z., & Chen, S. (2020) · BIO Integration · doi:10.15212/bioi-2020-0035 · Cited by 10
Self-citationMedication use during COVID-19
Ng, T. S. B., Leblanc, K., Yeung, D. F., & Tsang, T. S. M. (2021) · Canadian Family Physician · doi:10.46747/cfp.6703171 · Cited by 9
Sakurai, K., Chubachi, S., Asakura, T., Namkoong, H., Tanaka, H., Azekawa, S., Shimada, T., Otake, S., Nakagawara, K., Fukushima, T., et al. (2023) · Hypertension Research · doi:10.1038/s41440-023-01490-w · Cited by 9
Considerações sobre a relação entre a hipertensão e o prognóstico da COVID-19
de Barros, G. M., Filho, J. B. R. M., & Júnior, A. M. C. (2020) · Journal of Health & Biological Sciences · doi:10.12662/2317-3076jhbs.v8i1.3250.p1-3.2020 · Cited by 9
What every orthopaedic surgeon should know about COVID-19: A review of the current literature
Yung, C. S.-Y., Fok, K. C. H., Leung, G. C. N., & Wong, Y. W. (2020) · Journal of orthopaedic surgery · doi:10.1177/2309499020923499 · Cited by 9
Wang, M., Fu, D., Yao, L., & Li, J. (2020) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207323666200806164635 · Cited by 9
Fogacci, S., Fogacci, F., Favari, E., Toth, P. P., Borghi, C., & Cicero, A. F. G. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa105 · Cited by 9
Jeffery, M. M., Cummins, N. W., Dempsey, T. M., LIMPER, A. H., Shah, N. D., & Bellolio, F. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-044010 · Cited by 9
The therapeutic effect and safety of the drugs for COVID-19
Qiu, R., Li, J., Xiao, Y., Gao, Z., Weng, Y., Zhang, Q., Wang, C., Gong, H., & Li, W. (2021) · Medicine · doi:10.1097/md.0000000000025532 · Cited by 9
Roy‐Vallejo, E., Purificación, A. S., Torres-Peña, J. D., Moreno, B. S., Arnalich, F., Blanco, M. J. G., López‐Miranda, J., Romero‐Cabrera, J. L., Gil, C. R. H., Bascuñana, J., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122642 · Cited by 9
Patel, U., Deluxe, L., Salama, C., Jimenez, A. R., Whiting, A., Lubin, C., & Tarlin, N. (2021) · Cureus · doi:10.7759/cureus.16427 · Cited by 8
Camelo, S., Latil, M., Agus, S., Dioh, W., Veillet, S., Lafont, R., & Dilda, P. J. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2006579 · Cited by 9
Matsoukas, J., Gadanec, L. K., Zulli, A., Apostolopoulos, V., Kelaidonis, K., Ligielli, I., Moschovou, K., Georgiou, N., Plotas, P., Chasapis, C. T., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10071731 · Cited by 9
Angiotensin‐converting enzyme as a new immunologic target for the new SARS‐CoV‐2
Hallaj, S., Ghorbani, A., Mousavi‐Aghdas, S. A., Mirza‐Aghazadeh‐Attari, M., Севбитов, А. В., Hashemi, V., Hallaj, T., & Jadidi‐Niaragh, F. (2020) · Immunology and Cell Biology · doi:10.1111/imcb.12396 · Cited by 8
Association of ACEi/ARB Use and Clinical Outcomes of COVID-19 Patients With Hypertension
Ma, J., Shi, X., Yu, J., Lv, F., Wu, J., Sheng, X., Pan, Q., Yang, J., Cao, H., & Li, L. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.577398 · Cited by 9
Correction of endothelial dysfunction in COVID 19
Teplova, N., & Grishin, D. V. (2020) · Medical alphabet · doi:10.33667/2078-5631-2020-22-56-59 · Cited by 9
Credible Protein Targets and Curative Strategies for COVID-19: a Review
Singh, P., Mishra, N., Singh, N., Nisha, R., Pal, R. R., Singh, S., Maurya, P., & Saraf, S. A. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00526-3 · Cited by 8
Stepanova, G. (2021) · Biologia Futura · doi:10.1007/s42977-021-00092-2 · Cited by 7
Leontsinis, I., Katsiki, N., Papademetriou, V., Chrysohoou, C. A., Kariori, M. G., Dalakouras, I., Tolis, P., Fragoulis, C., Kalos, T., Fotios-Panagiotis, T., et al. (2021) · Archives of Medical Science · doi:10.5114/aoms/141243 · Cited by 9
Renin-Angiotensin-Aldosterone System
Speth, R. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00160-2 · Cited by 8
Falahi, S., Maleki, M., & Kenarkoohi, A. (2022) · Infectious Disorders - Drug Targets · doi:10.2174/1871526522666220321153712 · Cited by 8
Zhao, J. V., Schooling, C. M., & Leung, G. M. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14572 · Cited by 8
Cai, X. J., Tay, J., Kui, S., Tin, A., & Tan, V. H. (2020) · Singapore Medical Journal · doi:10.11622/smedj.2020159 · Cited by 8
Laurentius, A., Mendel, B., & Prakoso, R. (2021) · The Egyptian Heart Journal · doi:10.1186/s43044-021-00135-y · Cited by 8
Chaudhari, S., Pereira, S. D., Asare-Werehene, M., Naha, R., Kabekkodu, S. P., Tsang, B. K., & Satyamoorthy, K. (2021) · Journal of Ovarian Research · doi:10.1186/s13048-021-00787-z · Cited by 8
Nadalin, S., Jakovac, H., Peitl, V., Karlović, D., & Buretić‐Tomljanović, A. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12250 · Cited by 8
Fernando, M. E., Drovandi, A. D., & Golledge, J. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01802-6 · Cited by 8
Does Losartan reduce the severity of COVID-19 in hypertensive patients?
Mirjalili, M., Soodejani, M. T., Raadabadi, M., Dehghani, A., & Salemi, F. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02548-2 · Cited by 8
ACEi/ ARB and Deaths of COVID-19 Patients
Kumar, A., & Azad, G. N. (2022) · Current Hypertension Reviews · doi:10.2174/1573402118666220407093332 · Cited by 8
Therapy with RAS inhibitors during the COVID-19 pandemic
Spaccarotella, C., Mazzitelli, M., Migliarino, S., Curcio, A., Rosa, S. D., Torti, C., & Indolfi, C. (2021) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001160 · Cited by 8
Menshawey, R., Menshawey, E., Alserr, A. H. K., & AbdelMassih, A. F. (2020) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000237 · Cited by 7
Whey-Derived Peptides at the Heart of the COVID-19 Pandemic
Chamata, Y., Jackson, K. G., Watson, K. A., & Jauregi, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111662 · Cited by 9
Krishnakumar, B., Christopher, J., Prasobh, P. S., Godbole, S. V., Mehrotra, A., Singhal, A., Roy, S., Bhattacharya, K., Kolte, N., Abhyankar, M., et al. (2022) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_973_21 · Cited by 7
COVID-19 in Relation to Chronic Antihistamine Prescription
Puigdellívol‐Sánchez, A., Juanes-González, M., Calderón-Valdiviezo, A., Losa-Puig, H., Valls-Foix, R., González-Salvador, M., Lozano-Paz, C., & Vidal‐Alaball, J. (2024) · Microorganisms · doi:10.3390/microorganisms12122589 · Cited by 7
Cardiovascular risk in COVID-19 infection.
Lubrano, V., & Balzan, S. (2020) · PubMed Central · Cited by 7
Georges, J., Gilles, F., Cochet, H., Bertrand, A., Tournemire, M. D., Monguillon, V., Pasqualini, M., Prevot, A., Roger, G., Saba, J., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0244349 · Cited by 7
Possible Benefit of Angiotensin II Receptor Blockers in COVID-19 Patients: A Case Series
Lee, S. J., Kim, T., Cho, W. H., Jeon, D., & Lim, S. (2021) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1155/2021/9951540 · Cited by 7
Relation Between Renin–Angiotensin–Aldosterone System Inhibitors and COVID-19 Severity
Alhaddad, M. J., Almulaify, M. S., Alshabib, A., Alwesaibi, A. A., Alkhameys, M. A., Alsenan, Z. K., Alsheef, H. J., Alsaghirat, M. A., Almomtan, M. S., & Alshakhs, M. N. (2022) · Cureus · doi:10.7759/cureus.22903 · Cited by 7
Existence of Quantum Pharmacology in Sartans: Evidence in Isolated Rabbit Iliac Arteries
Gadanec, L. K., Swiderski, J., Apostolopoulos, V., Kelaidonis, K., Vidali, V. P., Canko, A., Moore, G. J., Matsoukas, J., & Zulli, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417559 · Cited by 11
Review of evidence on using ACEi and ARBs in patients with hypertension and COVID-19
Khan, S. H., & Zaidi, S. K. (2020) · Drugs & Therapy Perspectives · doi:10.1007/s40267-020-00750-w · Cited by 7
Emerging therapeutics for the management of COVID 19
Debnath, S. K., Srivastava, R., & Omri, A. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1810663 · Cited by 7
The Renin-Angiotensin System, Hypertension, and SARS-CoV-2 Infection: a Review
Gathiram, P., Mackraj, I., & Moodley, J. (2021) · Current Hypertension Reports · doi:10.1007/s11906-021-01134-9 · Cited by 7
The relationship between SARS-COV-2 RNA positive duration and the risk of recurrent positive
Zhao, H., Zhang, C., Chen, X.-X., Zhu, Q., Huang, W., Zeng, Y., Liu, Y., Li, G., Du, W.-J., Yao, J., et al. (2021) · Infectious Diseases of Poverty · doi:10.1186/s40249-021-00831-6 · Cited by 7
Feng, B., Zhang, D., Wang, Q. M., Yu, F., Zou, Q., Xie, G., Wang, R., Yang, X., Chen, W., Lou, B., et al. (2021) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2000730 · Cited by 7
COVID-19 desde una perspectiva cardiovascular
Bryce, A., Bryce‐Alberti, M., Portmann-Baracco, A., Urquiaga-Calderón, J., Vigna, C. A. L., & Valdivia, E. A. (2020) · Archivos de cardiología de México · doi:10.24875/acm.20000304 · Cited by 9
Inverse association between hypertension treatment and COVID-19 prevalence in Japan
Kinoshita, M., Sato, K., Vellingiri, B., Green, S. J., & Tanaka, M. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.05.071 · Cited by 7
Barochiner, J., & Martínez, R. (2020) · medRxiv · doi:10.1101/2020.05.19.20106799 · Cited by 7
Metadata
- Authors
- Meng, J., Xiao, G., Zhang, J., He, X., Ou, M., Bi, J., Yang, R., Di, W., Wang, Z., Li, Z., Gao, H., Liu, L., & Zhang, G.
- Affiliations
- Southern University of Science and Technology (CN)
- Shenzhen Bay Laboratory (CN)
- Corresponding author
- Gao, Hong
- Liu, Lei
- Zhang, Guoliang
- ORCID
- Venue
- Emerging Microbes & Infections
- Publisher
- Informa UK Limited
- Published
- 2020-01
- Volume
- 9
- Issue
- 1
- Pages
- 757-760
- ISSN
- 2222-1751 (ISSN-L)
- PMC
- PMC7170368
- OpenAlex
- W3013871850
- Cited by
- 619
- References
- 14
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 22 · 2023: 31 · 2022: 61 · 2021: 194 · 2020: 297
- FWCI
- 19.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Emerging Microbes & Infections (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- ImmPort
- Funders
- National Natural Science Foundation of China (81873958)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- COVID-19 pandemic, hypertension, renin-angiotensin system, ACE inhibitors, angiotensin receptor blockers, SARS-CoV-2, interleukin-6, T-cell count, viral load, antihypertensive therapy
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Aged, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, C-Reactive Protein, China, Female, Humans, Hypertension, Male, Middle Aged, Pneumonia, Viral, Renin-Angiotensin System, Retrospective Studies, Interleukin-6, Treatment Outcome, CD3 Complex, Coronavirus Infections, CD8-Positive T-Lymphocytes, Viral Load, Angiotensin II Type 1 Receptor Blockers, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
